(Q35136174)

6 August 2017

1 reference

title

Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma (English)

1 reference

6 August 2017

Mickisch GH

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

43

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

670-679

1 reference

Guidelines on renal cell cancer

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900105-2

7 January 2021

10.1016/S0302-2838(03)00105-2

Identifiers

DOI

1 reference

6 August 2017

1 reference